Optimizing Steroid Treatment for Duchenne Muscular Dystrophy


Summary Research funded in part by the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) has revealed insights into glucocorticoid steroid treatment for Duchenne muscular dystrophy (DMD). Scientists determined mechanisms of how glucocorticoid steroids improve muscle repair and function in mouse models of acute muscle injury and muscular dystrophy, according to a study in The Journal of Clinical Investigation . In a second paper in The Lancet , an international team found that in patients with DMD, long-term glucocorticoid steroid treatment delayed loss of muscle strength and function and decreased risk of death. Background DMD is a

The Role of the Microbiota in Eczema: Findings Suggest That Striking the Right Balance Keeps the Disease at Bay


*/ Research suggests that the bacterium, Staphylococcus aureus , plays a role in the skin condition, atopic dermatitis. Credit: Heidi H. Kong, M.D., M.H.Sc., National Institute of Arthritis and Musculoskeletal and Skin Diseases. Microbes living on the skin are coming under increasing scrutiny as the cause of the most common type of eczema, called atopic dermatitis. A new pair of studies focus specifically on the bacterium Staphylococcus aureus as playing a role in driving the disorder. The studies – one from the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the other from the University of

NIH program to accelerate therapies for arthritis, lupus releases first datasets


Datasets characterizing individual cells in rheumatoid arthritis and systemic lupus erythematosus disease tissue from the Accelerating Medicines Partnership for Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Phase I study are now available to the research community. Scientists from across the biomedical research community can access the AMP RA/SLE datasets to explore important research questions about these autoimmune conditions. “This pioneering program seeks to speed the development of new ways to combat a range of devastating diseases that affect millions of people,” said National Institutes of Health Director Francis S. Collins, M.D, Ph.D. “AMP RA/SLE is entering an exciting phase

NIAMS Update — February 22, 2018


*/ /*--> */ /*--> */ /*--> */ SPOTLIGHT Letter From Dr. Stephen I. Katz: From Basic Science to Clinical Breakthroughs—the NIAMS Intramural Research Program Dear Colleagues, The first NIAMS Advisory Council meeting of the year gives the Institute an opportunity to share progress with members about the activities of the NIAMS Intramural Research Program (IRP). The annual presentations from NIAMS Scientific Director John J. O’Shea, M.D., and Clinical Director Richard Siegel, M.D., Ph.D., are a special highlight for me. These talks illustrate how the IRP exemplifies the best qualities of the National Institutes of Health (NIH) Intramural Research Program —

NIAMS Awards Five Centers of Research Translation


Continuing its commitment to support translational research, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health announces five Centers of Research Translation (CORT) (P50) awards. CORTs foster the application of basic research to human diseases within the NIAMS mission. Synergistic teams of scientists carry out these programs to address significant translational research challenges. Each CORT contains a minimum of three highly meritorious research components: one or more translational research projects, one or more research cores, and an administrative core. Through the CORTs, investigators identify new therapeutic targets, develop treatments or diagnostics, or

NIAMS Awards Five New Core Centers for Clinical Research


The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health announces five new Core Centers for Clinical Research (CCCR) (P30) awards. The CCCRs provide avenues to advance the methodological sciences that support clinical research within and across the NIAMS' scientific portfolio. The overall goal of the CCCRs is to develop and apply methods, metrics, and outcome measures that address existing and emerging clinical research needs to advance the prevention, diagnosis, and treatment of musculoskeletal, rheumatologic, and skin diseases. Based on internal review, along with inputs from an externally convened Centers Evaluation Working Group

NIAMS Community Outreach Bulletin — Winter 2018


*/ /*--> */ /*--> */ /*--> */ Feature Story New Year, New Website: Fresh Resources for Your Community Visit the new NIAMS redesigned website to find reliable health information even faster! The new site uses a responsive design so that it can be easily viewed on a phone, tablet or computer. The Health Topics are listed in an A-Z directory and by general categories. Many topics are also available in Spanish , Chinese , Korean and Vietnamese . Some of the new features include: Health Topics that are available in modules with featured sections, such as symptoms, causes and treatment,

NIAMS Update — December 14, 2017


*/ /*--> */ /*--> */ /*--> */ SPOTLIGHT Letter From Dr. Stephen I. Katz: Strengthening Our Partnership With the NIAMS Coalition Dear Colleagues, The 2017 NIAMS Coalition Outreach and Education Day marked a decade since the inaugural event. From its inception, we have worked diligently to build innovative partnerships and research programs to connect science with the public. The NIAMS Coalition is a consortium of more than 90 professional and voluntary organizations that are national in scope. These groups serve as key partners in advancing our mission, and we rely on them to help further public understanding about diseases and
Subscribe to